• Total H1 FY25 revenues of $3.8 million, up 17% on PCP
• Costs tightly managed while supporting growth objectives
• Cash position remains strong at $4.5 million
• Expanded reach to 99% of all pharmacies in New Zealand market

Pharmx Technologies Limited (ASX: PHX) is pleased to announce its interim results for the half-year ended 31 December 2024. Pharmx continues to deliver a strong start to FY25, outperforming forecasts with accelerated growth and cost management driving robust results. Total H1 FY25 revenues were $3.8 million, up 17% on the previous corresponding period. FY25 H1 costs have been tightly managed while supporting the company's growth objectives, and the cash position remains strong at $4.5 million. Pharmx has also secured a commercial agreement with Toniq, expanding its reach to 99% of all pharmacies in the New Zealand market. Additionally, the company has terminated the revenue share agreement with Alchemy relating to the acquisition of the Pharmxchange intellectual property, reducing the amount payable under the agreement by $0.8 million. Pharmx's growth strategy for FY25 has resulted in a 10% increase in supplier partners and a 4% increase in the total number of Gateway accounts, contributing to a 13% uplift in recurring revenue. The company has also seen significant growth in its Marketplace, with a 235% increase in the number of orders placed and a 1,070% increase in the value of invoices processed compared to H1 FY24. Pharmx has completed a rebranding initiative to align with its ambitious growth objectives and reinforce its leadership in the pharma-tech sector.

Pharmx expects to continue its strong financial performance in FY25, with revenue growth and cost management driving robust results. The company remains in a strong financial position, with capacity to invest in the growth of the business.

Pharmx is focused on expanding supplier participation, increasing pharmacy engagement, boosting transaction volumes, and enhancing analytics capabilities to grow its addressable market. The company is also refining existing solutions and introducing new services to better support pharmacies, suppliers, and point-of-sale vendors.